[
  {
    "ts": null,
    "headline": "SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts",
    "summary": "Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.",
    "url": "https://finnhub.io/api/news?id=bc7c9d9a7440d9d0956206996e2510fd4d4c426c16525ca877e7e9736849a332",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755018120,
      "headline": "SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts",
      "id": 136321135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.",
      "url": "https://finnhub.io/api/news?id=bc7c9d9a7440d9d0956206996e2510fd4d4c426c16525ca877e7e9736849a332"
    }
  },
  {
    "ts": null,
    "headline": "Reasons to Add Veeva Systems Stock to Your Portfolio for Now",
    "summary": "VEEV's strong first quarter, product innovations and strategic deals drive growth prospects despite rising costs.",
    "url": "https://finnhub.io/api/news?id=4513415e80b937a674ba533c72eabee702be6345ccfc1b95da6844046787c23c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755013260,
      "headline": "Reasons to Add Veeva Systems Stock to Your Portfolio for Now",
      "id": 136320683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "VEEV's strong first quarter, product innovations and strategic deals drive growth prospects despite rising costs.",
      "url": "https://finnhub.io/api/news?id=4513415e80b937a674ba533c72eabee702be6345ccfc1b95da6844046787c23c"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Industry Outlook Highlights McKesson, Cardinal Health, West Pharmaceutical Services and The Cooper Companies",
    "summary": "Despite tariff headwinds and softer elective procedure demand, McKesson, Cardinal Health, West Pharmaceutical Services, and The Cooper Companies are positioned for steady gains in the dental supplies space.",
    "url": "https://finnhub.io/api/news?id=99f1a6af2ee9acc73d7e4827ce4c0c9434d8ce1d2eb10cce60bd384f9eb0160a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755010680,
      "headline": "Zacks Industry Outlook Highlights McKesson, Cardinal Health, West Pharmaceutical Services and The Cooper Companies",
      "id": 136320820,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "Despite tariff headwinds and softer elective procedure demand, McKesson, Cardinal Health, West Pharmaceutical Services, and The Cooper Companies are positioned for steady gains in the dental supplies space.",
      "url": "https://finnhub.io/api/news?id=99f1a6af2ee9acc73d7e4827ce4c0c9434d8ce1d2eb10cce60bd384f9eb0160a"
    }
  },
  {
    "ts": null,
    "headline": "CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls",
    "summary": "Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.",
    "url": "https://finnhub.io/api/news?id=044386165fd55d02dbada5f107f17b214d31055e917f26c91a2ba27c6c948250",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755009420,
      "headline": "CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls",
      "id": 136320684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.",
      "url": "https://finnhub.io/api/news?id=044386165fd55d02dbada5f107f17b214d31055e917f26c91a2ba27c6c948250"
    }
  }
]